GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Forward Dividend Yield %

Radiopharm Theranostics (Radiopharm Theranostics) Forward Dividend Yield % : 0.00% (As of Jun. 19, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Forward Dividend Yield %?

As of today (2024-06-19), the Forward Annual Dividend Yield of Radiopharm Theranostics is 0.00%.

As of today (2024-06-19), the Trailing Annual Dividend Yield of Radiopharm Theranostics is 0.00%.

RDPTF's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful Forward Dividend Yield % only.

Radiopharm Theranostics's Dividends per Share for the six months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Radiopharm Theranostics's Forward Dividend Yield %

For the Biotechnology subindustry, Radiopharm Theranostics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Forward Dividend Yield % falls into.



Radiopharm Theranostics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Radiopharm Theranostics  (OTCPK:RDPTF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Radiopharm Theranostics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022